Effects of <sup>ch</sup>aducanumab‐mediated plaque removal on amyloid‐tau synergy
Within a more-complex neuropathological environment, amyloid immunotherapy influences plaque-related secondary disease events, but does not directly impact tau deposition in the APP/PS1xTau22 mouse model. Identifying which aspects of the AD pathology remain resistant to amyloid immunotherapy will provide insight into how mono- or combination therapies can be developed or improved.
Authors
- Anastasie Maté de Gérando (ORCID: https://orcid.org/0000-0001-6733-1507)
- Thierry Bussière (ORCID: https://orcid.org/0000-0002-6818-4876)
- Anita Khasnavis (ORCID: https://orcid.org/0009-0007-7218-3503)
- Luc Buée (ORCID: https://orcid.org/0000-0002-6261-4230)
- Jonah C Meltzer
- Lindsay A Welikovitch
- Bradley T. Hyman (ORCID: https://orcid.org/0000-0002-7959-9401)
- Harshil Bhavsar
Institutions
- Biogen (United States) (US)
- Harvard University (US)
- Université de Lille (FR)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1002/alz.091508
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00